News

Nurix Therapeutics Announces Formation of Decart Therapeutics to Advance New Car T Therapies Using Targeted Protein Modulation

SAN FRANCISCO, June 25, 2020 – Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix. DeCART plans to combine the use of Nurix’s proprietary targeted protein modulation drugs with the … Nurix Therapeutics Announces Formation of Decart Therapeutics to Advance New Car T Therapies Using Targeted Protein Modulation Read More »

Read More
Scroll to Top